The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Lebwohl David since 2021.
This trader's CIK number is 1810882.
At the time of last reporting, Lebwohl David was the EVP, Chief Medical Officer of Intellia Therapeutics, Inc.. (stock ticker symbol NTLA).
Also see all insider trading activities at Intellia Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | NTLA | 0 | $0 | 9,557 | $116,404 | 0 | $0 |
| 2024 | NTLA | 0 | $0 | 5,843 | $172,134 | 0 | $0 |
| 2023 | NTLA | 0 | $0 | 0 | $0 | 6,374 | $0 |
| 2022 | NTLA | 0 | $0 | 1,051 | $117,964 | 3,187 | $0 |
| 2021 | NTLA | 0 | $0 | 12,000 | $1,761,376 | 19,923 | $251,423 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-03 | NTLA | Sale | 9,557 | 12.18 | 116,404 |
| 2024-01-03 | NTLA | Sale | 5,843 | 29.46 | 172,134 |
| 2023-01-01 | NTLA | Option Ex | 3,187 | .00 | 0 |
| 2023-01-01 | NTLA | Option Ex | 3,187 | .00 | 0 |
| 2022-01-01 | NTLA | Option Ex | 3,187 | .00 | 0 |
| 2022-01-01 | NTLA | Sale | 1,051 | 112.24 | 117,964 |
| 2021-11-05 | NTLA | Option Ex | 2,400 | 12.62 | 30,287 |
| 2021-11-05 | NTLA | Sale | 2,400 | 133.44 | 320,244 |
| 2021-10-14 | NTLA | Option Ex | 2,400 | 12.62 | 30,287 |
| 2021-10-14 | NTLA | Sale | 2,400 | 128.81 | 309,139 |
| 2021-09-24 | NTLA | Option Ex | 7,923 | 12.62 | 99,988 |
| 2021-09-21 | NTLA | Option Ex | 2,400 | 12.62 | 30,287 |
| 2021-09-21 | NTLA | Sale | 2,400 | 149.81 | 359,544 |
| 2021-08-30 | NTLA | Option Ex | 2,400 | 12.62 | 30,287 |
| 2021-08-30 | NTLA | Sale | 2,400 | 157.80 | 378,729 |
| 2021-08-09 | NTLA | Option Ex | 2,400 | 12.62 | 30,287 |
| 2021-08-09 | NTLA | Sale | 2,400 | 164.05 | 393,720 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Lebwohl David (EVP, Chief Medical Officer of Intellia Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.